1. Home
  2. ATXS

ATXS

Astria Therapeutics Inc.

Logo Astria Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 10:30am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Founded: 2008 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 613.3M IPO Year: 2015
Target Price: $21.75 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.42 EPS Growth: N/A
52 Week Low/High: $4.26 - $16.90 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: